Viewing Study NCT05353166


Ignite Creation Date: 2025-12-24 @ 4:32 PM
Ignite Modification Date: 2026-01-04 @ 3:43 AM
Study NCT ID: NCT05353166
Status: COMPLETED
Last Update Posted: 2025-06-11
First Post: 2022-04-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
Sponsor: Regeneron Pharmaceuticals
Organization:

Study Overview

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonist, in Heart Failure Patients With Elevated Pulmonary Capillary Wedge Pressure
Status: COMPLETED
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Detailed Description: Note: Group A has stopped enrolling and Group B will not enroll participants

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2021-006337-19 EUDRACT_NUMBER None View
2023-506674-13-00 CTIS None View